Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best mid-cap stocks that could double your money.
On May 28, Lake Street assigned a Buy rating to Viking Therapeutics Inc. (NASDAQ:VKTX) while setting a price target at $89
This leads to an upside potential of more than 211% at the prevailing level. RAJ CREATIONZS / According to the firm, this stance is driven by the market opportunity for VK2735, the company’s lead clinical asset for obesity. VK2735 is projected to generate approximately $3 billion in risk-adjusted worldwide sales by the year 2040.
Additionally, the firm noted the potential for further financial upside stemming from the company’s earlier-stage pipeline assets. On May 27, Truist published a report on Viking Therapeutics Inc. (NASDAQ:VKTX) with a Buy rating and a price target of $83, indicating a 191% upside. The firm highlighted the company as a distinct competitor within a crowded and highly aggressive obesity treatment market.